2024 GCCW _ Overview of Conference Program (November 5th)
- 관리자
- 2024.10.21
- 50
Program Overview
[Morning Session – Global Commercialization Strategies for Advanced Biotechnology]
The program introduces the Global Industrial Technology Cooperation Center project and international collaborative research support programs of the Ministry of Trade, Industry and Energy, introduces the current status of KAIST's GCC bio field, which has been selected as an NCC, introduces the research activities of Yale University, Georgia Institute of Technology, and Johns Hopkins University related to the bio field among the Global Industrial Technology Cooperation Centers (GITCC), and explains how to identify, plan, and propose projects between domestic and foreign research teams for joint R&D.
Following a keynote speech on the government's industrial technology R&D projects and support policies in the bio sector and an introduction to the technologies selected as international joint R&D projects, the panel discussion will discuss the need for international joint research in the bio sector and ways to cooperate with global research institutions.
We have prepared presentations on topics suitable for domestic and international business professionals, industry experts, researchers, venture capitalists, university and graduate students in the bio field, and provide simultaneous Korean and English support for online and offline attendees.
[Afternoon Session – AI Driven Drug Discovery]
Collaborations between big pharmaceutical companies and AI drug discovery companies are dramatically reducing the enormous cost and time involved in the drug discovery process, and research and industrialization are progressing in parallel. In September of this year, Google DeepMind open-sourced Alphafold3, an AI model for protein generation, which can predict the interactions of proteins with biomolecules in the human body, and is expected to dramatically accelerate the development of new drugs and therapies.
This year, three co-winners of the Nobel Prize in Chemistry (including Professor David Baker at the University of Washington) were awarded for their contributions to the discovery of new proteins and the development of AlphaFold2, a tool for predicting the three-dimensional structure of proteins using AI, and in the United States, one of leading countries in AI drug discovery, more than 1,000 AI drug discovery startups are created every year, and investment from venture capita firms is also strong.
In the afternoon session, we will look at the current status of AI drug discovery and development in Korea, including the government's advanced biotechnology initiatives, the current status of AI drug discovery and development at home and abroad, and strategies to support AI drug discovery and development. We will also look at the information needed to attract VC from specialized companies and prospective founders, and the legal issues of training data in the process of AI drug discovery and development. In the panel discussion that follows, we will gather experts from industry and academia to discuss advanced AI drug discovery and development R&D and global expansion.
After the conference, there will be a separate 30-minute meeting between the speakers and attendees to network with bio and AI drug discovery companies for investment and legal advice, and to discuss research topics in research institutes and universities.
This conference is sponsored by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA) Convergence AI Institute for Drug Discovery(CAIID), and registration fee is free. If you would like to participate, please apply using the following link. Thank you.